On September 15, 2025, Qualigen Therapeutics, Inc. amended its secured promissory note with Marizyme, Inc., correcting the maturity date to August 21, 2026 and increasing the outstanding principal by $75,000, now totaling $4,526,462.18. This event is significant for the company and reflects a neutral sentiment from an equity investor perspective.